Goldman Sachs
APGE icon

Goldman Sachs’s Apogee Therapeutics APGE Stock Holding History

Goldman Sachs’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225M Buy
1,693,341
+1,040,751
+159% +$93.8M 0.02% 733
2026
Q1 		$54.9M Buy
652,590
+87,180
+15% +$6.33M 0.01% 1505
2025
Q4 		$42.7M Sell
565,410
-34,206
-6% -$2.15M 0.01% 1640
2025
Q3 		$23.8M Sell
599,616
-59,570
-9% -$2.27M ﹤0.01% 2099
2025
Q2 		$28.6M Buy
659,186
+368,487
+127% +$14M ﹤0.01% 1802
2025
Q1 		$10.9M Sell
290,699
-117,320
-29% -$4.54M ﹤0.01% 2621
2024
Q4 		$18.5M Buy
408,019
+250,562
+159% +$12.8M ﹤0.01% 2204
2024
Q3 		$9.25M Sell
157,457
-179,696
-53% -$8.61M ﹤0.01% 2810
2024
Q2 		$13.3M Buy
337,153
+224,161
+198% +$10.9M ﹤0.01% 2239
2024
Q1 		$7.51M Buy
112,992
+85,241
+307% +$3.72M ﹤0.01% 2742
2023
Q4 		$775K Buy
27,751
+17,749
+177% +$356K ﹤0.01% 4526
2023
Q3 		$213K Buy
+10,002
New +$220K ﹤0.01% 5024

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Goldman Sachs's APGE Position: Q2 2026 in Review

Goldman Sachs increased its Apogee Therapeutics (APGE) stake by 159% in Q2 2026, buying an estimated $93.8M and bringing the position to 1,693,341 shares worth $225M. The position accounts for 0.02% of the portfolio, ranked #733.

Goldman Sachs first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Goldman Sachs held 1,693,341 shares of Apogee Therapeutics worth $225M as of Q2 2026.
  • Goldman Sachs bought 1,040,751 Apogee Therapeutics shares in Q2 2026, an estimated $93.8M.
  • Apogee Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q2 2026, its #733 holding.
  • Goldman Sachs first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.